Immunocore Appoints Andrew Hotchkiss as Chief Commercial Officer

Immunocore Limited, the world’s leading TCR company developing biological drugs to treat cancer, infectious diseases and autoimmune diseases, today announces the appointment of Andrew Hotchkiss as Chief Commercial Officer (CCO).